IMNM
Immunome Inc.
Latest close $25.52 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 2 of 2 parsed filing(s)| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management CIK0001897612 | Mar 31, 2026 observed May 15, 2026 filed · 45d Schedule 13G amendment | Reported accumulation | 16.4M +5.7M | 14.50% +2.30 pts | $21.87 | $20.88 | $25.52 |
| T. Rowe Price Investment Management CIK0001897612 | Oct 31, 2025 observed Nov 7, 2025 filed · 7d Initial Schedule 13G | Initial Schedule 13G | 10.6M | 12.20% | $25.52 |